EL7.AI
StocksMedium•11 November 2026•
4 min read

Inhibrx Begins Search for New CEO After 23 Years Under Jay R. Luly

Key Facts

1Jay R. Luly plans to retire by February 1, 2027, after leading Inhibrx for 23 years.
2Inhibrx announced the retirement plan and began its search for a successor on October 28, 2026.
3Luly will continue as a strategic adviser through the rest of 2027 to support an orderly transition.
4Tara Kiefer joined Inhibrx in 2020 and was appointed to the newly created role of chief operating officer.
5The company expects initial data from the Phase 2b portion of the RESOLVE trial in 2027.

Inhibrx Pharmaceuticals announced on October 28, 2026, that CEO Jay R. Luly plans to retire by February 1, 2027, after leading the company for 23 years. The company said its board has begun a comprehensive search for his successor, considering internal and external candidates. The announcement marks a planned leadership transition, with Luly remaining a strategic adviser through the end of 2027 to support what the company described as a smooth and orderly handover. Inhibrx did not name a successor or set a date for selecting one. The board said its goal is to choose a leader to guide the company’s next phase of growth as its pipeline programs advance.

The company said the search will include internal and external candidates, and that the board is seeking a leader to guide Inhibrx’s next phase of growth as it continues developing its drug programs. That goal places the selection process in the context of ongoing pipeline work, alongside arrangements for the CEO transition. The company confirmed that Luly will continue to advise through the rest of 2027, allowing for a transition period that extends beyond his planned retirement date. The statement did not set a timeline for completing the search or announcing a successor. It also did not indicate whether a decision had been made about potential candidates.

As part of the leadership reshuffle, Inhibrx appointed Tara L. Kiefer, Ph.D., as chief operating officer, a role newly created by the company. Before her appointment, Kiefer served as head of product strategy and joined Inhibrx in 2020. Her career before joining the company included 16 years at Vertex Pharmaceuticals, spanning research and clinical development, integrated program management and business development. Her appointment adds a new executive role ahead of the company’s expected leadership change. The statement did not say that her appointment determines who will succeed Luly as CEO.

Luly said in the company statement that he has spent 43 years in the pharmaceutical and biotechnology industries, including 23 years as Inhibrx’s CEO. He expressed enthusiasm for the company’s pipeline as he discussed his decision to retire. The difference between his years of industry experience and his tenure at the company reflects a career spanning more than four decades, including more than two decades leading Inhibrx. The company’s management page says Luly has led it since July 2003, and describes him as its chairman, CEO and a member of its board. The announced retirement plan sets an end to this phase of leadership by February 1, 2027.

Chairman Bruce L. A. Carter praised Luly’s contribution to developing the company’s business, citing his role in helping deliver curative treatments for hepatitis C infections, as well as potential treatments for respiratory syncytial virus and immune diseases. The praise places Luly’s leadership experience within the record of the company’s therapeutic programs as the board prepares to search for its next leader. In drug development, Inhibrx announced on October 26 that the first patient had been dosed in the global Phase 2b/3 RESOLVE trial of zilucoplan against respiratory syncytial virus. The company said initial data from the Phase 2b portion are expected in 2027. The trial is one of the programs the company will continue to advance during the leadership transition.

The latest financial results in the company’s disclosures show revenue of $14.4 million for the fiscal quarter ended June 30, 2026, compared with $18.3 million in the corresponding period of 2025. Net loss in the same quarter was $19.5 million, versus $18.3 million a year earlier. As of June 30, 2026, cash and marketable securities totaled $211.5 million. Inhibrx said at the time that its current resources and retained royalty proceeds were expected to fund operations through fiscal 2029. These figures provide financial context as the board prepares to select a new leader, though the retirement statement did not link the succession search to specific financial expectations.

The company statement set November 16, 2026, as the date for releasing results for its fourth fiscal quarter. The date follows the retirement plan and search announcement, while the proposed transition arrangements extend through the rest of 2027. The statement did not announce a date for completing the CEO selection, making the financial results the next specified date on the company’s calendar. The company is also expecting initial data from the Phase 2b portion of the RESOLVE trial during 2027, according to its announcement about the trial. The search for Luly’s successor will proceed alongside these stated milestones.

Open on chart